Who regulates your veterinary cold chain? USDA biologics vs FDA animal drugs

Why care which agency licensed the vial? Because the paperwork, the labeling rules, the recall mechanics, and the person who answers your compliance question all differ — and because knowing where the rules stop tells you exactly how much of your cold chain is your own engineering responsibility. That turns out to be most of it.

The split, product by product

The line falls in a stranger place than “vaccines vs. everything else.” Three monoclonal antibodies sit in the same product class and split across two agencies. A 2025 review in the journal Animals states the rule directly:

“The USDA Center for Veterinary Biologics approves mAbs that target the immune system, while the FDA Center for Veterinary Medicine approves mAbs that have targets other than the immune system.”

Current Review of Monoclonal Antibody Therapeutics in Small Animal Medicine, Animals, 2025

So Cytopoint, which targets an immune cytokine, is a USDA-licensed biologic; Librela and Solensia, which target nerve growth factor, are FDA-approved new animal drugs — Solensia in January 2022 as the first monoclonal antibody the FDA had approved for any animal species, Librela in May 2023 as the first for dogs (dvm360, 2022 and 2023). Same refrigerator shelf, different statutes.

What the USDA framework says about temperature — and where it stops

USDA’s authority runs through the Virus-Serum-Toxin Act of 1913, which makes it unlawful to prepare or sell any “worthless, contaminated, dangerous, or harmful virus, serum, toxin, or analogous product intended for use in the treatment of domestic animals” and requires production at a USDA-licensed establishment (21 U.S.C. § 151). APHIS’s Center for Veterinary Biologics administers the program to ensure veterinary biologics are “pure, safe, potent, and effective” (USDA APHIS, Veterinary Biologics program).

On temperature, the regulation is a labeling rule. 9 CFR 112.2(a)(4) requires final container labels to carry a “storage temperature recommendation for the biological product stated as 2 to 8 °C or 35 to 46 °F, or both.” That single sentence is why virtually every vaccine carton in animal health reads 35–46°F: refrigerated storage is the regulatory default for the entire biologics category. (The frozen exceptions — cell-associated poultry vaccines labeled for liquid nitrogen storage — are handled at the product-license level; the mechanism is not spelled out in §112.2 itself.)

And that is roughly where it stops. Part 112 governs what licensed establishments put on labels; the 9 CFR biologics regulations are aimed at manufacturers, not at the distributor, retailer, or clinic shipping a parcel downstream. We could find no USDA requirement that a downstream shipper use a qualified or validated shipping container, and no transit-excursion standard equivalent to USP’s controlled cold temperature definition. The label states the condition; keeping the product in it between the warehouse and the ranch gate is left to the parties handling it.

What the FDA framework says — and where it stops

FDA’s Center for Veterinary Medicine approves and regulates animal drugs under the Federal Food, Drug, and Cosmetic Act (FDA, Animal & Veterinary program). Storage conditions ride on the approved labeling: Librela’s product information reads “Store and transport refrigerated (2°C–8°C). Do not freeze” (Zoetis SPC), and Vetsulin’s label reads “Store in an upright position under refrigeration at 2°C to 8°C (36°F to 46°F). Do not freeze” (DailyMed). Manufacturers and distributors operate under cGMP and licensing obligations; pharmacies dispensing and shipping to pet owners answer to state boards of pharmacy.

What FDA-CVM does not impose is a parcel-level distribution standard. On the human side, USP <1079> and <1079.5> describe good storage and distribution practice for drug products, and state rules and accreditation programs increasingly pull those chapters into enforceable expectations for pharmacies — see direct-to-patient shipping and USP <1079>. Animal health has no equivalent pull. The chapters exist, the physics is identical, but nothing downstream of the veterinary label makes a chamber-qualified shipper mandatory.

No mandate — so why does everyone serious validate anyway?

Three reasons, none of them regulatory.

• Risk economics. A spoiled refrigerated shipment costs the product, the reship, the carrier claim fight, and the client’s afternoon. Chamber-qualifying a packout is a one-time cost amortized over every parcel that follows; eating excursion losses is a recurring one. The arithmetic favors validation long before any inspector does.
• Accreditation and network standards. Pharmacy accreditation programs and the retail networks that route veterinary prescriptions increasingly ask distribution-practice questions borrowed from the human side — see URAC and ACHC shipping requirements. Voluntary today has a way of becoming contractual tomorrow.
• Client trust. The pet owner who receives a warm box does not parse the USDA/FDA distinction. They parse whether they trust you with the next shipment.

This is the argument for treating veterinary cold chain to the human-pharmacy standard even where no rule requires it: qualification against your lanes and seasons, documented hold times, and evidence in the box. Meridian’s packouts are chamber-tested by a third party to hold 2–8°C for their rated 48- or 72-hour windows — the same bar we hold for human pharmacy product, because the parcel cannot tell the difference either.